The reactive rates for R-HCV (0.1%), R-HBV (0.4%), and R-HIV (0%) in the NAT test suggest the effectiveness of this method in reducing the window period for the detection of these infections, thus enhancing blood safety [20]. This evidence concerns the gene BRD2 and infection.